380885-39-2

Basic information

• Product Name: Sulfamoyl chloride, [[(4-methylphenyl)amino]carbonyl]-
• Synonyms: Sulfamoyl chloride,[[(4-methylphenyl)amino]carbonyl]
• CAS NO: 380885-39-2
• Molecular Formula: C8H9ClN2O3S
• Molecular Weight: 248.69
• Mol File: 380885-39-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Sulfamoyl chloride, [[(4-methylphenyl)amino]carbonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Sulfamoyl chloride, [[(4-methylphenyl)amino]carbonyl]-(380885-39-2)
• EPA Substance Registry System: Sulfamoyl chloride, [[(4-methylphenyl)amino]carbonyl]-(380885-39-2)

Safety Data

• Hazardous Substances Data: 380885-39-2(Hazardous Substances Data)

Upstream product

• 1189-71-5 isocyanate de chlorosulfonyle 
• 106-49-0 p-toluidine 

Downstream Products

• 153439-24-8 C₁₁H₁₄N₂O₅S 
• 609-55-2 2-amino-5-methyl-benzenesulfonamide 
• 477932-77-7 N-(4-methyl-2-sulfamoyl-phenyl)-malonamic acid ethyl ester 
• 71254-63-2 7-methyl-3-oxo-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide 

Relevant articles and documents

An efficient one-pot synthesis of N-(substituted phenyl)-1,2,5-thiadiazolidine-2-carboxamide 1,1-dioxide derivatives

1,2,5-Thiadiazolidine-1,1-dioxide carboxamide derivatives 3a-3n are novel heterocyclic compounds synthesized by multicomponent condensation reaction in one pot of aniline, chlorosulfonyl isocyanate, and 2-chloroethylamine hydrochloride which is used as a

Tetrahydrocoptisine derivative and applications thereof

The present invention relates to a compound as shown in a formula (VII), a preparation method and applications thereof in medicines. In particular, the present invention relates to a derivative of the compound as shown in the formula (VII), a preparation method, and the applications of the derivative used as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, II-type diabetes, hyperglycemia, obesity or insulin resistance syndrome and metabolic syndrome. The compound disclosed by the present invention can also reduce total cholesterol, LDL-cholesterol and triglyceride, and increases expression of a liver LDL receptor and decreases expression of PCSK9.

Inhibitors of HCV NS5B polymerase: Synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring

A series of non-nucleoside HCV NS5B polymerase inhibitors based on the N-1-benzyl or N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine core substituted in the D-ring aromatic moiety have been prepared and evaluated. Aromatic substituents extending from position 7 of the D-ring exhibited excellent potency against both genotypes 1a and 1b.